News

The decision follows a pre-planned review of safety data. RHB-104 is an antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties. It has

REKOVELLE is the first rFSH to be derived from a human cell line and is the first rFSH treatment to be administered with an individualised dosing regimen. REKOVELLE’s

Proton Partners will invest £30m in its cancer centre which will be located at the Thames Valley Science Park and will offer proton beam therapy among other conventional

Up to 200 new jobs will be created at the Rockville facility, with GSK investing over $50m in the next two years to continue to develop the site

SAGE-217 is a next generation positive allosteric modulator that has been optimized for selectivity to synaptic and extrasynaptic GABA receptors and a pharmacokinetic profile aimed for daily oral

Qutenza is approved by the European Medicines Agency (EMA) for the treatment of peripheral neuropathic pain (PNP). Grünenthal will hold exclusive rights for Qutenza in all 28 European

When used along with diet and exercise, SYNJARDY XR is indicated to improve blood sugar in adults with type 2 diabetes when both empagliflozin and metformin can be

Brennan is the former Chief Executive Officer and Executive Director of AstraZeneca and has been a member of the Alexion Board of Directors since July 2014. Brennan succeeds

BlueRock Therapeutics will develop induced pluripotent stem cell (iPSC) therapies for treating various diseases. The funds are expected to give the new company at least four years of runway and enable